Answers are grounded in this paper and cite their sources.
Background Antibody-drug conjugates (ADCs) are increasingly prescribed in anti-tumor treatment; however, metabolism and nutrition disorders (MNDs) during ADC therapy remain insufficiently characterized. We evaluated short-term nutritional changes after inotuzumab ozogamicin (INO) in a pediatric relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) cohort and separately assessed ADC-associated MND reporting signals in the FDA Adverse Event Reporting System (FAERS). Methods We identified 146 children with R/R B-ALL who initiated INO or non-INO salvage therapy between January 2014 and June 2025. Of these, 143 had evaluable body-weight measurements at baseline and 1 month and comprised the primary endpoint population, including 73 patients treated with INO and 70 treated with non-INO salvage therapy. The primary endpoint was body weight change from baseline to 1 month after treatment initiation, with clinically significant weight change defined as an absolute change of ≥5% from baseline. Propensity scores were estimated using treatment assignment (INO vs. non-INO) as the dependent variable, followed by 1:1 nearest-neighbor matching without replacement (caliper, 0.10); 34 matched pairs were included, and clinically significant weight change was analyzed using matched-pair methods. In parallel, FAERS reports from January 2004 through September 2024 were analyzed using reporting odds ratios (RORs) to identify disproportionate MND reporting signals, and univariate logistic regression was used to explore report-level correlates. Set-based analyses were used to assess co-reporting patterns of MNDs with recorded death or disease progression. Results Pediatric patients with R/R B-ALL receiving INO showed a higher frequency of clinically significant weight change than matched patients receiving non-INO salvage therapy (24/34 vs. 7/34; exact McNemar p < 0.001). In FAERS, MNDs accounted for 8.1% of ADC-associated AE reports, with an overall disproportionate reporting signal (ROR, 1.72; 95% CI, 1.67–1.78). Among MND reports, 11.5% also reported death or disease progression. Microtubule inhibitor ADCs showed slightly higher MND reporting odds than non-microtubule inhibitor ADCs (OR, 1.17; 95% CI, 1.04–1.32; p = 0.009). ADCs also showed disproportionate reporting of several nutritional complications compared with conventional chemotherapy. Conclusion In the pediatric cohort, INO treatment was associated with greater short-term weight changes than non-INO salvage therapy, while FAERS identified disproportionate reporting signals for several MNDs across ADCs. These findings highlight the potential importance of nutritional evaluation and individualized nutritional support during ADC therapy, although their clinical benefits require further prospective evaluation.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: